IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Biocon and Optimer Sign API Manufacturing Deal

11:04 PM MDT | May 26, 2010 | Deepti Ramesh

Biotechnology company and manufacturing services provider Biocon (Bangalore, India) says it has entered into a long-term supply agreement with biopharmaceutical company Optimer Pharmaceuticals (San Diego, CA) for the commercial manufacturing of the active pharmaceutical ingredient (API) fidaxomicin - Optimer's lead product candidate for the treatment of clostridium difficile infection (CDI). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of CDI and Optimer has reported positive top-line results from two Phase 3 trials of...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa